Magnetic Nanoclusters Stabilized with Poly[3,4-Dihydroxybenzhydrazide] as Efficient Therapeutic Agents for Cancer Cells Destruction.
apoptosis
magnetic hyperthermia
magnetic nanoclusters
membrane pathway
oxidative stress
p53 pathway
poly[3,4-dihydroxybenzhydrazide]
polydopamine analogues
solvothermal method
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
03 Mar 2023
03 Mar 2023
Historique:
received:
16
02
2023
revised:
01
03
2023
accepted:
02
03
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
12
3
2023
Statut:
epublish
Résumé
Magnetic structures exhibiting large magnetic moments are sought after in theranostic approaches that combine magnetic hyperthermia treatment (MH) and diagnostic magnetic resonance imaging in oncology, since they offer an enhanced magnetic response to an external magnetic field. We report on the synthesized production of a core-shell magnetic structure using two types of magnetite nanoclusters (MNC) based on a magnetite core and polymer shell. This was achieved through an in situ solvothermal process, using, for the first time, 3,4-dihydroxybenzhydrazide (DHBH) and poly[3,4-dihydroxybenzhydrazide] (PDHBH) as stabilizers. Transmission electron microscopy (TEM) analysis showed the formation of spherical MNC, X-ray photoelectronic spectroscopy (XPS) and Fourier transformed infrared (FT-IR) analysis proved the existence of the polymer shell. Magnetization measurement showed saturation magnetization values of 50 emu/g for PDHBH@MNC and 60 emu/g for DHBH@MNC with very low coercive field and remanence, indicating that the MNC are in a superparamagnetic state at room temperature and are thus suitable for biomedical applications. MNCs were investigated in vitro, on human normal (dermal fibroblasts-BJ) and tumor (colon adenocarcinoma-CACO2, and melanoma-A375) cell lines, in view of toxicity, antitumor effectiveness and selectivity upon magnetic hyperthermia. MNCs exhibited good biocompatibility and were internalized by all cell lines (TEM), with minimal ultrastructural changes. By means of flowcytometry apoptosis detection, fluorimetry, spectrophotometry for mitochondrial membrane potential, oxidative stress, ELISA-caspases, and Western blot-p53 pathway, we show that MH efficiently induced apoptosis mostly via the membrane pathway and to a lower extent by the mitochondrial pathway, the latter mainly observed in melanoma. Contrarily, the apoptosis rate was above the toxicity limit in fibroblasts. Due to its coating, PDHBH@MNC showed selective antitumor efficacy and can be further used in theranostics since the PDHBH polymer provides multiple reaction sites for the attachment of therapeutic molecules.
Identifiants
pubmed: 36903811
pii: nano13050933
doi: 10.3390/nano13050933
pmc: PMC10005337
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii
ID : PN-III-P1-1.1-TE-2021-0498
Références
Nanomaterials (Basel). 2021 Apr 30;11(5):
pubmed: 33946316
ACS Nano. 2017 Jul 25;11(7):6808-6816
pubmed: 28625045
Int J Hyperthermia. 2013 Dec;29(8):828-34
pubmed: 24219800
Pigment Cell Melanoma Res. 2014 Jan;27(1):8-10
pubmed: 24118922
Chem Asian J. 2013 Jul;8(7):1447-54
pubmed: 23616374
Pharmaceutics. 2023 Jan 10;15(1):
pubmed: 36678868
Bioconjug Chem. 2008 Dec;19(12):2375-84
pubmed: 19053308
J Photochem Photobiol B. 2015 Oct;151:142-52
pubmed: 26257158
Cancers (Basel). 2019 Aug 01;11(8):
pubmed: 31374895
Micromachines (Basel). 2022 Aug 08;13(8):
pubmed: 36014201
ACS Appl Mater Interfaces. 2020 Sep 30;12(39):43474-43487
pubmed: 32870658
Angew Chem Int Ed Engl. 2019 Feb 11;58(7):1904-1927
pubmed: 30221440
J Photochem Photobiol B. 2016 Aug;161:402-10
pubmed: 27314538
Hum Mutat. 2007 Jun;28(6):578-88
pubmed: 17295241
Pharmaceutics. 2020 May 06;12(5):
pubmed: 32384665
Nanomaterials (Basel). 2022 May 25;12(11):
pubmed: 35683663
Int J Hyperthermia. 2011;27(6):563-72
pubmed: 21846192
Biomater Sci. 2022 May 4;10(9):2103-2121
pubmed: 35316317
Molecules. 2022 Jan 01;27(1):
pubmed: 35011493
Front Chem. 2021 May 14;9:674786
pubmed: 34055744
Nanomaterials (Basel). 2021 Jul 09;11(7):
pubmed: 34361173
Cancers (Basel). 2021 Sep 12;13(18):
pubmed: 34572810
Stem Cell Res Ther. 2022 Apr 1;13(1):135
pubmed: 35365206
Bio Protoc. 2019 Nov 5;9(21):
pubmed: 32699812
Nanomaterials (Basel). 2021 Nov 10;11(11):
pubmed: 34835777
ACS Omega. 2017 Oct 26;2(10):7172-7184
pubmed: 31457296
Inorg Chem. 2017 Jul 17;56(14):8232-8243
pubmed: 28671822
Cell Biol Int. 2008 Aug;32(8):1001-5
pubmed: 18534870
Asian J Pharm Sci. 2019 Nov;14(6):581-594
pubmed: 32104485
ACS Appl Mater Interfaces. 2020 Jul 29;12(30):33483-33491
pubmed: 32614594
Angew Chem Int Ed Engl. 2005 Apr 29;44(18):2782-2785
pubmed: 15798982
Antioxid Redox Signal. 2008 Oct;10(10):1713-65
pubmed: 18707220
Dalton Trans. 2015 Feb 21;44(7):2943-52
pubmed: 25564784
Materials (Basel). 2021 Oct 10;14(20):
pubmed: 34683540
Pharmaceutics. 2021 Feb 24;13(3):
pubmed: 33668307
Nanotechnology. 2011 Dec 2;22(48):485706
pubmed: 22071878
Int J Mol Sci. 2015 Oct 15;16(10):24417-50
pubmed: 26501258
Mater Sci Eng C Mater Biol Appl. 2019 Aug;101:575-587
pubmed: 31029351
ACS Nano. 2012 Dec 21;6(12):10935-49
pubmed: 23167525
Nano Converg. 2018;5(1):4
pubmed: 29492374
Nanomedicine (Lond). 2014 Dec;9(18):2729-43
pubmed: 24547783
Front Pharmacol. 2018 Aug 02;9:831
pubmed: 30116191
Nanoscale. 2020 Nov 5;12(42):21647-21656
pubmed: 32766635
Int J Nanomedicine. 2011;6:373-80
pubmed: 21499427
Int J Mol Sci. 2014 Sep 29;15(10):17380-95
pubmed: 25268613
PLoS One. 2013 Sep 04;8(9):e75044
pubmed: 24023970
Pharmaceutics. 2022 Nov 05;14(11):
pubmed: 36365207
J Biol Chem. 2000 Jul 14;275(28):21094-8
pubmed: 10781588
Birth Defects Res A Clin Mol Teratol. 2003 Nov;67(11):929-40
pubmed: 14745931
Molecules. 2016 Oct 13;21(10):
pubmed: 27754394
Molecules. 2020 Jun 22;25(12):
pubmed: 32580417
PLoS One. 2014 Nov 06;9(11):e111960
pubmed: 25375144
Biomaterials. 2012 Jun;33(18):4515-25
pubmed: 22445482
Nano Lett. 2016 Dec 14;16(12):7455-7460
pubmed: 27960458
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32916798
Int J Pharm. 2019 Feb 10;556:57-67
pubmed: 30529663
Int J Nanomedicine. 2019 Dec 06;14:9677-9692
pubmed: 31827324
Front Bioeng Biotechnol. 2021 Aug 19;9:720508
pubmed: 34490227
Int J Hyperthermia. 2014 Nov;30(7):513-23
pubmed: 25354680
Adv Mater. 2016 Jul;28(27):5400-24
pubmed: 27411644
ACS Omega. 2021 Nov 10;6(46):31161-31167
pubmed: 34841158
Nanomedicine. 2019 Aug;20:101983
pubmed: 30940505
Int J Mol Sci. 2022 Nov 25;23(23):
pubmed: 36499070
Front Oncol. 2022 Mar 16;12:836397
pubmed: 35372087
Nanoscale. 2015 Feb 7;7(5):1768-75
pubmed: 25515238
Nanomaterials (Basel). 2019 Oct 18;9(10):
pubmed: 31635415
J Phys Chem B. 2018 Jun 21;122(24):6314-6327
pubmed: 29787272
Materials (Basel). 2021 Oct 26;14(21):
pubmed: 34771940
Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:187-93
pubmed: 26478302
Chem Soc Rev. 2012 Nov 7;41(21):6874-87
pubmed: 22868949